Monmouth Junction-based biotech firm Advaxis Inc. announced Jan. 19 it closed its previously announced merger with Ayala Pharmaceuticals Inc., a clinical-stage oncology company headquartered in ...
When perusing the biotech sector, investors have more than 300 publicly traded companies on reputable exchanges that they can choose from. It's almost overwhelming, and it can make finding a company ...
With $20 million on hand and the second part of a potentially registrational phase 2/3 study just getting underway, Ayala was facing a potential cash crunch. But Advaxis may have solved its ...
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--The European Patent Court in Munich, Germany has ruled in favor of Advaxis Incorporated (OTCBB: ADXS) and reversed a patent challenge made by Anza Therapeutics, ...
Because a number of shareholders had expressed concern that the apparent success of the Merck drug diminished the potential role of Lovaxin C.Princeton-based Advaxis (Nasdaq: ADXS) has issued ...
PRINCETON, N.J., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products ...
First two patients treated in the combination arm who previously progressed on KEYTRUDA® showed substantial tumor shrinkage with ADXS-503 treatment in combination with KEYTRUDA® Partial response ...
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company developing cancer immunotherapies, today announced that it will host its annual Investor & Analyst ...
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announced it ...
PRINCETON, N.J., March 13, 2017 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a biotechnology company developing cancer immunotherapies, today announced that Sara Bonstein, Chief Financial Officer ...
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results